← Leaderboards
Julia V Busik
Michigan State University
$11,064,375
Attributed
$15,357,610
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,357,610 · 6
By mechanism
R01$15,058,610 · 5
R21$299,000 · 1
Top collaborators
- Maria B Grant14 shared
- Irina A Pikuleva6 shared
- Michael Edwin Boulton4 shared
- Denis A Proshlyakov4 shared
Others in their field
Top investigators on “Diabetic Retinopathy”
- John M Lachin · George Washington University$140,240,809
- David M Nathan · Massachusetts Institute Of Technology$123,291,647
- Rose A Gubitosi-Klug · Case Western Reserve University$71,942,336
- Rohit Varma · University Of Southern California$56,244,772
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Adam R Glassman · Jaeb Center For Health Research, Inc.$50,075,374
Research focus
Diabetic RetinopathyDiabetes MellitusCellsRetinaDiabeticInflammatoryInflammationBlood VesselsPathogenesisDyslipidemiasPreventMediatingLipidsBone MarrowRepairedChronicAffectTissuesPathway InteractionsPathologyCeramidesEnzymesProductionEndothelium
Grant awards (41)
Anti-ceramide immunotherapy for diabetic retinopathy$422,886
R01 · FY2025 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$390,876
R01 · FY2025 · EY · contact PI
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$320,663
R01 · FY2025 · EY
Dyslipidemia and Diabetic Retinopathy$390,876
R01 · FY2024 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$388,770
R01 · FY2024 · EY
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$379,250
R01 · FY2024 · EY
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$403,500
R01 · FY2023 · EY
Dyslipidemia and Diabetic Retinopathy$390,876
R01 · FY2023 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$388,770
R01 · FY2023 · EY
Anti-ceramide immunotherapy for diabetic retinopathy$380,243
R01 · FY2022 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$379,150
R01 · FY2022 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$377,107
R01 · FY2022 · EY
Cholesterol homeostasis in pathogenesis of DR$50,490
R01 · FY2022 · EY
Dyslipidemia and Diabetic Retinopathy$405,001
R01 · FY2021 · EY · contact PI
Anti-ceramide immunotherapy for diabetic retinopathy$380,566
R01 · FY2021 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$377,106
R01 · FY2021 · EY
Ceramide-mediated mitochondrial damage in diabetic retinopathy investigated by novel microfluidic O2 sensing and bio-mimetic electrochemistry$361,178
R01 · FY2021 · EY
Cholesterol homeostasis in pathogenesis of DR$413,020
R01 · FY2020 · EY
Anti-ceramide immunotherapy for diabetic retinopathy$392,577
R01 · FY2020 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$373,053
R01 · FY2020 · EY · contact PI
Ceramide-mediated mitochondrial damage in diabetic retinopathy investigated by novel microfluidic O2 sensing and bio-mimetic electrochemistry$372,932
R01 · FY2020 · EY
Anti-ceramide immunotherapy for diabetic retinopathy$406,120
R01 · FY2019 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$373,512
R01 · FY2019 · EY · contact PI
Ceramide-mediated mitochondrial damage in diabetic retinopathy investigated by novel microfluidic O2 sensing and bio-mimetic electrochemistry$373,492
R01 · FY2019 · EY
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$522,331
R01 · FY2018 · EY
Dyslipidemia and Diabetic Retinopathy$373,954
R01 · FY2018 · EY · contact PI
Ceramide-mediated mitochondrial damage in diabetic retinopathy investigated by novel microfluidic O2 sensing and bio-mimetic electrochemistry$368,531
R01 · FY2018 · EY
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$555,127
R01 · FY2017 · EY
Dyslipidemia and Diabetic Retinopathy$374,379
R01 · FY2017 · EY · contact PI
LXR as a novel therapeutic target in diabetic retinopathy$532,879
R01 · FY2016 · EY
Dyslipidemia and Diabetic Retinopathy$388,163
R01 · FY2016 · EY · contact PI
LXR as a novel therapeutic target in diabetic retinopathy$582,429
R01 · FY2015 · EY
Dyslipidemia and Diabetic Retinopathy$364,415
R01 · FY2014 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$353,651
R01 · FY2013 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$372,654
R01 · FY2012 · EY · contact PI
Dyslipidemia and Diabetic Retinopathy$386,023
R01 · FY2011 · EY · contact PI
Dyslipidemia and diabetic retinopathy$318,137
R01 · FY2007 · EY · contact PI
Dyslipidemia and diabetic retinopathy$325,576
R01 · FY2006 · EY · contact PI
Dyslipidemia and diabetic retinopathy$348,347
R01 · FY2005 · EY
Dyslipidemia and retinal endothelial cell dysfunction$149,500
R21 · FY2004 · DK
Dyslipidemia and retinal endothelial cell dysfunction$149,500
R21 · FY2003 · DK